---
title: Heterogeneous HER2 Amplificationâ€”a New Clinical Category of HER2-Positive Breast Cancer?
tags:
  - HER2 Amplification
  - Breast Cancer
  - Drug Resistance
  - Trastuzumab

author: Hossein Fallahi
member: Hossein Fallahi
---
HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways.
See related [paper](https://aacrjournals.org/cancerdiscovery/article/11/10/2369/665574/XSLT_Related_Article_Replace_Href) in Cancer Discovery.
